IBDEI1IW ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24652,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,24653,0)
 ;;=B19.10^^85^1086^26
 ;;^UTILITY(U,$J,358.3,24653,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24653,1,3,0)
 ;;=3^Hepatitis B w/o Hepatic Coma
 ;;^UTILITY(U,$J,358.3,24653,1,4,0)
 ;;=4^B19.10
 ;;^UTILITY(U,$J,358.3,24653,2)
 ;;=^5000552
 ;;^UTILITY(U,$J,358.3,24654,0)
 ;;=B17.10^^85^1086^27
 ;;^UTILITY(U,$J,358.3,24654,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24654,1,3,0)
 ;;=3^Hepatitis C w/o Hepatic Coma,Acute
 ;;^UTILITY(U,$J,358.3,24654,1,4,0)
 ;;=4^B17.10
 ;;^UTILITY(U,$J,358.3,24654,2)
 ;;=^5000542
 ;;^UTILITY(U,$J,358.3,24655,0)
 ;;=B18.2^^85^1086^28
 ;;^UTILITY(U,$J,358.3,24655,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24655,1,3,0)
 ;;=3^Hepatitis C,Chr/Carrier
 ;;^UTILITY(U,$J,358.3,24655,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,24655,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,24656,0)
 ;;=E03.9^^85^1086^42
 ;;^UTILITY(U,$J,358.3,24656,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24656,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,24656,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,24656,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,24657,0)
 ;;=E16.2^^85^1086^39
 ;;^UTILITY(U,$J,358.3,24657,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24657,1,3,0)
 ;;=3^Hypoglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,24657,1,4,0)
 ;;=4^E16.2
 ;;^UTILITY(U,$J,358.3,24657,2)
 ;;=^5002708
 ;;^UTILITY(U,$J,358.3,24658,0)
 ;;=E78.1^^85^1086^34
 ;;^UTILITY(U,$J,358.3,24658,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24658,1,3,0)
 ;;=3^Hyperglyceridemia,Pure
 ;;^UTILITY(U,$J,358.3,24658,1,4,0)
 ;;=4^E78.1
 ;;^UTILITY(U,$J,358.3,24658,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,24659,0)
 ;;=E78.5^^85^1086^37
 ;;^UTILITY(U,$J,358.3,24659,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24659,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,24659,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,24659,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,24660,0)
 ;;=E87.1^^85^1086^38
 ;;^UTILITY(U,$J,358.3,24660,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24660,1,3,0)
 ;;=3^Hypo-osmolatlity & Hyponatremia
 ;;^UTILITY(U,$J,358.3,24660,1,4,0)
 ;;=4^E87.1
 ;;^UTILITY(U,$J,358.3,24660,2)
 ;;=^5003019
 ;;^UTILITY(U,$J,358.3,24661,0)
 ;;=E87.5^^85^1086^35
 ;;^UTILITY(U,$J,358.3,24661,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24661,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,24661,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,24661,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,24662,0)
 ;;=E87.6^^85^1086^40
 ;;^UTILITY(U,$J,358.3,24662,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24662,1,3,0)
 ;;=3^Hypokalemia
 ;;^UTILITY(U,$J,358.3,24662,1,4,0)
 ;;=4^E87.6
 ;;^UTILITY(U,$J,358.3,24662,2)
 ;;=^60610
 ;;^UTILITY(U,$J,358.3,24663,0)
 ;;=G81.90^^85^1086^19
 ;;^UTILITY(U,$J,358.3,24663,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24663,1,3,0)
 ;;=3^Hemiplegia,Unspec
 ;;^UTILITY(U,$J,358.3,24663,1,4,0)
 ;;=4^G81.90
 ;;^UTILITY(U,$J,358.3,24663,2)
 ;;=^5004120
 ;;^UTILITY(U,$J,358.3,24664,0)
 ;;=G81.91^^85^1086^18
 ;;^UTILITY(U,$J,358.3,24664,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24664,1,3,0)
 ;;=3^Hemiplegia Affecting Right Dominant Side
 ;;^UTILITY(U,$J,358.3,24664,1,4,0)
 ;;=4^G81.91
 ;;^UTILITY(U,$J,358.3,24664,2)
 ;;=^5004121
 ;;^UTILITY(U,$J,358.3,24665,0)
 ;;=G81.92^^85^1086^17
 ;;^UTILITY(U,$J,358.3,24665,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24665,1,3,0)
 ;;=3^Hemiplegia Affecting Left Dominant Side
